Thanks Buck, "fellow RVX mushroom". That is a perfect description. Just trying to get things straight in my own head.

So there was 19,480,127 shares sold in exempt distributions since the AGM in the spring of 2022. It would be very revealing to trace if chunks of these shares have been bought up by any one of Efung, CTS Chins Fund, NGN, CD Ventures or even Protair. This would signal support from those who are probably privy to information not shared with us retail shareholders. I would be particularly interested if CD Ventures or NGN Capital increased their positions.

Regarding paying out the debenture, if Hepa extends it for another year, to me, it will hint of another year of compacency to come.

It seems completely remarkable that given FDA Break Through Designation, the scientifically supported Covid potential, the many other indications that warrant research on apbetalone, that rivers of money are not flowing into RVX. I don't think scientific issues are the barrier. I think the smart money must be extremely skeptical about the senior management's competence (or integrity) and/or their ability to replace this management team. 

Of course, if in fact their have been presentations to BPs, and the price RVX wants is too high, then that could be the explanation for the complete lack of progress in 3 years.

Either way, it is a remarkable squandering of high potential medical assets.

Let's hope that this latest phase of mushroom management is some sort of undeclared blackout period with a pot of gold waiting at the end.

GLTA

Toinv